ABEO
HealthcareAbeona Therapeutics Inc.
$5.22
$-0.09 (-1.69%)
Jan 5, 2026
Price History (1Y)
Analysis
Abeona Therapeutics Inc. is a biotechnology company in the healthcare sector with a market cap of $282.88M and 136 employees. The company's financial health is marked by significant losses, as evidenced by an EBITDA of -$80,984,000 and a Net Income (TTM) of $82.35M. This results in Operating Margin and Profit Margin of -20,802.2% and 20,587.5%, respectively. Abeona's financials also show a strong Return on Equity of 75.9%, but a negative Return on Assets of -29.6%. The company has $207.12M in cash and $24.11M in debt. Abeona Therapeutics Inc.'s valuation metrics include a P/E Ratio (TTM) of 4.39, Forward P/E of -74.57, and Price to Book of 1.60. The company's Revenue (TTM) is $400,000, with a Gross Margin of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Visit website →Key Statistics
- Market Cap
- $282.88M
- P/E Ratio
- 4.39
- 52-Week High
- $7.54
- 52-Week Low
- $3.93
- Avg Volume
- 1.72M
- Beta
- 1.12
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 136